New form of Taxol approved.

Share this article:

Bristol-Myers Squibb's Taxol and Sanofi-Aventis' Taxotere have new competition with a new FDA approval. The new drug, Abraxane –which is manufactured by American Pharmaceutical Partners, was approved for women with advanced breast cancer who have not responded to chemotherapy Abraxane features an easier administration and avoids some side effects.
In its clinical trial involving 460 women, tumors shrank in 21.5 percent of those who got Abraxane compared with 11.1 percent of those who received Taxol. The company has not yet provided data on whether Abraxane extended the lives of those women.
The women getting Abraxane in the trial had fewer cases of severe neutropenia, a decrease in white blood cells that can leave a patient vulnerable to infections. Some side effects like nerve damage, severe pain in the muscles or joints, and vomiting were more common with Abraxane.
American Pharmaceutical Partners, based in Schaumburg, Ill., is a generic maker that, with Abraxane, is moving into branded drugs.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Social media perceived as clinical trial risk

The Wall Street Journal reports that patients are sharing a plethora of information about their clinical trial experiences, from how to get picked, to how to figure out who is in a control group.

Cancer PSA features scientists

Stand Up To Cancer is kicking off a PSA that features Grammy-winner Jennifer Hudson and a Genentech scientist.

Lawmakers eye pricing

The Senate Judiciary Committee's antitrust panel is looking into how three major pharmaceutical manufacturers decided to set minimum prices for their contact lenses.